Spyre Therapeutics (SYRE) Exchange Rate Effect (2020 - 2024)
Spyre Therapeutics' (SYRE) quarterly Exchange Rate Effect came in at -$15000.0 in Q4 2024, down 183.33% YoY from $18000.0 in Q1 2024, and down 193.75% on a QoQ basis from $16000.0 in Q3 2024.
Spyre Therapeutics (SYRE) Exchange Rate Effect (2020 - 2024) Analysis & Trends
Spyre Therapeutics (SYRE) has 5 years of Exchange Rate Effect data on file, last reported at -$15000.0 in Q4 2024.
- Quarterly Exchange Rate Effect fell 183.33% year-over-year to -$15000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$15000.0 (down 150.0% YoY) and the FY2024 annual result came in at -$3000.0, down 112.0% from the prior year.
- Exchange Rate Effect eased to -$15000.0 in Q4 2024, from $16000.0 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $47000.0 in Q4 2020 to a low of -$72000.0 in Q2 2022.
- A 5-year average of -$3250.0 and a median of $3500.0 in 2021 frame the typical range for Exchange Rate Effect.
- The widest YoY moves for Exchange Rate Effect: up 1433.33% in 2022, down 1900.0% in 2022.
- Tracing SYRE's Exchange Rate Effect over 5 years: stood at $47000.0 in 2020, then slumped by 93.62% to $3000.0 in 2021, then surged by 1433.33% to $46000.0 in 2022, then plunged by 60.87% to $18000.0 in 2023, then tumbled by 183.33% to -$15000.0 in 2024.
- The last three Exchange Rate Effect figures came in at -$15000.0 (Q4 2024), $16000.0 (Q3 2024), and -$4000.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -15,000.00 |
| Dec 31, 2024 | -15,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Mar 31, 2024 | -4,000.00 |
| Mar 31, 2024 | -4,000.00 |
| Dec 31, 2023 | 18,000.00 |
| Dec 31, 2023 | 18,000.00 |
| Sep 30, 2023 | -17,000.00 |
| Sep 30, 2023 | -17,000.00 |
| Jun 30, 2023 | 13,000.00 |
| Jun 30, 2023 | 13,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Dec 31, 2022 | 46,000.00 |
| Dec 31, 2022 | 46,000.00 |
| Sep 30, 2022 | -57,000.00 |
| Sep 30, 2022 | -57,000.00 |
| Jun 30, 2022 | -72,000.00 |
| Jun 30, 2022 | -72,000.00 |